Dr Reddy's launches Finasteride tablets in US

The drug, which has US sales of $136 million, gets 180-day marketing exclusivity

Hyderabad-based drug firm Dr Reddy’s Laboratories Limited (DRL) has launched Finasteride Tablets (1 mg), a bio-equivalent generic version of Propecia (Finasteride) tablets in the US market on January 02.

Dr Reddy’s abbreviated new drug application (ANDA) for Finasteride 1 mg tablets has been awarded a 180-day period of marketing exclusivity in the US on 2 Jan, 2013, the company said in a filing to the Bombay Stock Exchange (BSE) .

The Propecia tablets brand has US sales of approximately $136 million medication assisted treatment (MAT) for the most recent twelve months ending in October 2012 according to Health, the filing said.

Dr Reddy’s Finasteride Tablets 1 mg is available in bottle counts of 30 and 90.

The company's scrip is currently trading at Rs 1,884.60 on the BSE, up 2.55 per cent over the previous day's close of Rs 1,837.80.

image
Business Standard
177 22
Business Standard

Dr Reddy's launches Finasteride tablets in US

The drug, which has US sales of $136 million, gets 180-day marketing exclusivity

Itishree Samal  |  Hyderabad 

Hyderabad-based drug firm Dr Reddy’s Laboratories Limited (DRL) has launched Finasteride Tablets (1 mg), a bio-equivalent generic version of Propecia (Finasteride) tablets in the US market on January 02.

Dr Reddy’s abbreviated new drug application (ANDA) for Finasteride 1 mg tablets has been awarded a 180-day period of marketing exclusivity in the US on 2 Jan, 2013, the company said in a filing to the Bombay Stock Exchange (BSE) .

The Propecia tablets brand has US sales of approximately $136 million medication assisted treatment (MAT) for the most recent twelve months ending in October 2012 according to Health, the filing said.

Dr Reddy’s Finasteride Tablets 1 mg is available in bottle counts of 30 and 90.

The company's scrip is currently trading at Rs 1,884.60 on the BSE, up 2.55 per cent over the previous day's close of Rs 1,837.80.

RECOMMENDED FOR YOU

Dr Reddy's launches Finasteride tablets in US

The drug, which has US sales of $136 million, gets 180-day marketing exclusivity

Dr Reddy’s abbreviated new drug application (ANDA) for Finasteride 1 mg tablets has been awarded a 180-day period of marketing exclusivity in the US on 2 Jan, 2013, the company said in a filing to the Bombay Stock Exchange (BSE) .

Hyderabad-based drug firm Dr Reddy’s Laboratories Limited (DRL) has launched Finasteride Tablets (1 mg), a bio-equivalent generic version of Propecia (Finasteride) tablets in the US market on January 02.

Dr Reddy’s abbreviated new drug application (ANDA) for Finasteride 1 mg tablets has been awarded a 180-day period of marketing exclusivity in the US on 2 Jan, 2013, the company said in a filing to the Bombay Stock Exchange (BSE) .

The Propecia tablets brand has US sales of approximately $136 million medication assisted treatment (MAT) for the most recent twelve months ending in October 2012 according to Health, the filing said.

Dr Reddy’s Finasteride Tablets 1 mg is available in bottle counts of 30 and 90.

The company's scrip is currently trading at Rs 1,884.60 on the BSE, up 2.55 per cent over the previous day's close of Rs 1,837.80.

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard